Clinical Trials | A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
The University of Virginia seeks adults age 18 years and older for a clinical trial. You may be eligible for this trial if you have recurrent endometrial cancer and have undergone at least 1 and no more than 3 prior lines of treatment. This study aims to evaluate a medication called mocertatug rezetecan (Mo-rez) compared to standard of care chemotherapy. If you participate in this study, you may be randomized (assigned by chance) to one of two arms: Arm 1: you will receive Mo-rez intravenously Arm 2: you will receive your physician’s choice of paclitaxel or doxorubicin intravenously This study will include: blood draws, tumor imaging assessments, echocardiogram (ECHO), questionnaires, tumor tissue collection, and physical examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. More information can be found here: https://clinicaltrials.gov/study/NCT07286331